Literature DB >> 15756286

Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.

A Jenke, J Freiberg-Richter, C Johne, H Knoth, E Schleyer, G Ehninger, M Bornhäuser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15756286     DOI： 10.1038/sj.bmt.1704831

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

2.  Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

Authors:  Christopher N Bredeson; Mei-Jie Zhang; Manza-A Agovi; Andrea Bacigalupo; Nizar J Bahlis; Karen Ballen; Christopher Brown; M Ahsan Chaudhry; Mary M Horowitz; Seira Kurian; Diana Quinlan; Catherine E Muehlenbien; James A Russell; Lynn Savoie; J Douglas Rizzo; Douglas A Stewart
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.